CLOs on the Move


 
ON TARGET LABORATORIES discovers and develops fluorescent markers to target and illuminate cancer during surgery so it can be removed more completely.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

TYME Inc

TYME is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles.

Perseus

Perseus is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adagio Therapeutics

Adagio Therapeutics, Inc` is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses` Our candidates are optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability` Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes` Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs` We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021` Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch`

BioMedica

BioMedica, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Gemelli Biotech

Gemelli Biotech leverages leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics which enable clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including SIBO, IMO, excess hydrogen sulfide and post-infectious IBS.